Loading…
Imunon, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in IMNN.
▼ -99.2% over 5Y.
today you would have $7.83▼ -99.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.81 | $12.39 | $8.87 | $17.61 | $105.65 | $138.91 | $334.57 | $275.87 | $524.35 | $821.74 | $5,259.13 | $6,382.17 | $10,655.22 | $101,051.70 | $20,975.32 | $25,293.77 | |
| P/S |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MBAIMBody AI Ltd. | $6.58 | 1.4x | 13.4x | — | — | $9.05M |
| TRAWTraws Pharma, Inc. | $0.59 | — | 5.3x | — | -433.36% | $9.07M |
| NDRAENDRA Life Sciences Inc. | $5.80 | — | 1.4x | — | -152.04% | $8.7M |
| IMRNImmuron Ltd | $1.15 |
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Company description provided by Yahoo Finance.
| 94.3x |
| — |
| — |
| — |
| 24.5x |
| 93.5x |
| 106.5x |
| 100.1x |
| 55.2x |
| 95.1x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/B | 2.1x | 2.1x | 3.3x | 0.5x | 0.4x | 0.8x | 2.9x | 3.4x | 1.3x | 1.8x | 2.5x | 2.2x | 1.4x | 2.1x | 34.8x | 2.2x | — |
| EPS | -$6.83 | -$16.94 | -$28.17 | -$65.61 | -$49.96 | -$131.48 | -$150.65 | -$133.04 | -$532.17 | -$2,326.30 | -$2,821.30 | -$3,780.00 | -$2,602.17 | -$9,422.61 | -$13,695.65 | -$18,754.41 |
| Profit margin | -4117.14% | — | — | — | -7179.65% | -4153.85% | -4296.71% | -3370.31% | -2376.67% | -4080.44% | — | — | — | — | — | — | — |
| ROE | -115.43% | -205.26% | -438.71% | -145.77% | -122.40% | -37.22% | -115.43% | -115.75% | -56.96% | -76.40% | -327.90% | -110.18% | -77.67% | -26.17% | -222.11% | -88.66% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.0x |
| — |
| -39.68% |
| $9.28M |
| EVGNEvogene Ltd. | $0.55 | — | — | — | -182.75% | $8.68M |
| XWELXWELL, Inc. | $1.01 | — | 20.6x | — | -361.36% | $8.68M |